The transplant many patients face
Autologous hematopoietic stem cell transplant (transplant using your own stem cells) is a standard treatment for several blood cancers. Before transplant, patients get high-dose chemotherapy to wipe out the disease. Their own previously collected stem cells are then infused back in to rebuild the blood system.
It works. But the chemo is brutal. Organs take damage. Some damage shows up years later, as heart trouble, kidney decline, new cancers, or autoimmune problems.
Doctors have been hunting for ways to protect those organs without weakening the cancer-fighting power.
Enter hyperbaric oxygen
Hyperbaric oxygen therapy, or HBO, involves breathing pure oxygen inside a pressurized chamber. It floods tissues with far more oxygen than normal breathing can deliver.
It is already used for diving injuries, certain wounds, and radiation damage. Early work in stem cell transplant showed it was safe and may help blood counts recover faster.
This study looked at the long-term picture. Do patients who get HBO before transplant actually do better years later?
The comparison, and its caveat
Researchers compared 19 patients who completed HBO before transplant to a historical control group of 225 patients who did not.
That number, 19, is the first thing to flag. It is small. The second flag is that the comparison group was historical, meaning pulled from past records, not assigned at the same time. Standards of care can drift over years, which muddies fair comparison.
With those limits noted, here is what they found.
The numbers that reached significance
Two endpoints crossed the standard statistical threshold.
Cardiac damage was 5.3% in the HBO group versus 23.9% in the historical group. That is a dramatic reduction if it holds up in a larger trial.
Kidney damage was 15.8% in the HBO group versus 42.8% in the historical group. Again, a large drop.
These two findings are the strongest signals in the paper.
The numbers that trended but did not prove
Several other outcomes pointed in the same direction but fell short of statistical significance.
Non-relapse mortality, meaning death from causes other than cancer return, was lower in the HBO group with a p-value of 0.057. That is right on the edge of significance.
Secondary malignancy, meaning new cancers unrelated to the original disease, occurred in 5.26% of HBO patients compared to 22.07% of controls. The p-value was 0.074, again just outside the threshold.
Autoimmune disease showed 0% in the HBO group versus 7.69% in the controls, but with a p-value of 0.14.
Median overall survival was not reached in the HBO cohort. In the historical cohort, it was 9 years. The p-value was 0.59, meaning no clear survival difference.
The pattern is consistent. Every outcome leans in HBO's favor. But the small sample means only the clearest differences passed statistical tests.
The oxygen-as-primer analogy
Think of the body before chemotherapy like a building about to be fumigated. The chemo kills the pests but also stresses the walls, plumbing, and wiring.
Hyperbaric oxygen may work like reinforcing that infrastructure first. Saturated tissues might handle the chemo stress better, leaving less long-term damage behind.
That is the working theory. The study is not designed to prove the exact mechanism. It measures outcomes only.
The safety read
HBO appeared well tolerated. No unusual side effects were flagged. The treatment is not trivial, though. Patients sit in a pressurized chamber for multiple sessions before transplant. That adds time, cost, and logistics to an already demanding process.
For centers without a nearby HBO facility, adding this step could be impractical.
Honest limits
The authors are upfront about the weaknesses.
Nineteen patients is too few for firm conclusions. Historical controls are a lower tier of evidence than concurrent controls, because patient mix, supportive care, and chemo regimens change over time.
Multiple comparisons were run. When you test many outcomes, some will cross statistical thresholds by chance alone. The cardiac and renal findings are the most striking, but they should be viewed as strong hypotheses, not proven facts.
And the study was retrospective. No one was assigned at random to get HBO or skip it. Selection bias, meaning differences in who got HBO versus who did not, could partly explain the results.
What this means right now
If you or a family member is preparing for autologous stem cell transplant, HBO is not a standard part of the process at most centers. This study does not change that overnight.
But it is worth asking your transplant team if they have experience with HBO or know of a trial. Some centers may offer it in research settings.
For the average patient, the standard focus remains managing the transplant itself and watching closely for long-term organ effects with regular follow-up care.
The clear next step is a prospective randomized trial. That would assign patients upfront to either HBO or no HBO, track them for years, and deliver a cleaner answer.
Until such a trial runs, HBO before transplant remains a promising but unproven strategy. The signals are encouraging enough that larger studies are justified.
For patients facing this already-demanding treatment, any tool that might protect the heart and kidneys years down the line is worth taking seriously.